Steranco Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for STERANCO HLTHCARE
STERANCO HLTHCARE has two approved drugs.
Drugs and US Patents for Steranco Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steranco Hlthcare | OXCARBAZEPINE | oxcarbazepine | SUSPENSION;ORAL | 220281-001 | Mar 9, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Steranco Hlthcare | NYSTATIN | nystatin | SUSPENSION;ORAL | 220367-001 | Feb 5, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

